

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 October 2010 (28.10.2010)

PCT

(10) International Publication Number
WO 2010/122344 A1

(51) International Patent Classification:
A61K 31/7016 (2006.01) *A61P 29/00* (2006.01)
A61K 31/702 (2006.01)

(21) International Application Number:
PCT/GB2010/050659

(22) International Filing Date:
23 April 2010 (23.04.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0906983.2 23 April 2009 (23.04.2009) GB
0920784.6 27 November 2009 (27.11.2009) GB

(71) Applicant (for all designated States except US): **CLASADO INC** [PA/PA]; Edificio Interseco, Piso 2, Calle Elvira Mendez, Apartado, Panama 0816-01560 (PA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TZORTZIS, Georgios** [GR/GB]; 1 Kiln View Road, Reading, Berkshire RG2 7RR (GB). **VULEVIC, Jelena** [GB/GB]; 1 Kiln View Road, Reading, Berkshire RG2 7RR (GB). **AT-TANASIO, Francesco** [IT/GB]; 62 Northumberland Avenue, Reading, Berkshire RG2 7PW (GB).

(74) Agent: **SAUNDERS & DOLLEYMORE LLP**; 9 Rickmansworth Road, Watford, Hertfordshire WD18 0JU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL USE

(57) Abstract: The present invention relates to the use of a galactooligosaccharide in the prevention or treatment of an inflammatory disorder, in particular an intestinal inflammatory disorder.



WO 2010/122344 A1

- 1 -

NOVEL USE

The present invention relates to the use of an oligosaccharide, in particular a galactooligosaccharide, in the prevention or treatment of inflammation, in particular in the prevention or treatment of intestinal inflammation. Galactooligosaccharides are non-digestible carbohydrates, which are resistant to mammalian gastrointestinal digestive enzymes but are fermented by specific colonic bacteria.

The human gut flora comprises pathogenic, benign and beneficial microbial genera. A predominance of the former can lead to intestinal disorders that can be both acute (eg gastroenteritis) and chronic (eg inflammatory bowel disease and some intestinal cancers).

Prebiotics, which are defined as a non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon, thereby resulting in an improvement in the health of the host, have been shown to have an indirect protective effect in a number of inflammatory conditions such as inflammatory bowel disease (IBD). It has been found in some IBD patients that the adaptive immune system is hyper-responsive to commensal intestinal flora (see Guarner F, Malagelada JR, Best Pract. Res. Clin. Gastroenterol., (2003); 17; 793-804). As a result, prebiotics have been used to enhance beneficial gut microflora which has helped to prevent a relapse in the disease (see Sartor RD., Gastroenterology, (2004), 126, 1620-1633).

One group of compounds that is classified as prebiotics are the galactooligosaccharides. These are galactose-containing oligosaccharides of the form Glc β 1-4 [Gal β 1-6]_n where n = 2 – 5 and are produced from lactose syrup using the transgalactosylase activity of the enzyme β -galactosidase (Crittenden, (1999) Probiotics : A Critical Review, Tannock, G. (ed) Horizon Scientific Press, Wymondham, pp 141-156).

EP 1 644 482 discloses a novel strain of *Bifidobacterium bifidum* that produces a

- 2 -

galactosidase enzyme activity that converts lactose to a novel mixture of galactooligosaccharides. This mixture of galactooligosaccharides comprises disaccharides Gal (β 1-3) Glc; Gal (β 1-3)-Gal; Gal (β 1-6)-Gal; Gal (α 1-6)-Gal; trisaccharides Gal (β 1-6)-Gal (β 1-4)-Glc; or Gal (β 1-3)-Gal (β 1-4)-Glc; tetrasaccharide Gal (β 1-6)-Gal (β 1-6)-Gal (β 1-4)-Glc or pentasaccharide Gal (β 1-6)-Gal (β 1-6)-Gal (β 1-6)-Gal (β 1-4)-Glc and has been shown to have prebiotic properties and to increase the population of the beneficial bacteria bifidobacteria and lactobacilli. This mixture of galactooligosaccharides is marketed commercially under the name Bimuno (Registered Trade mark) and is available from Clasado Ltd (Milton Keynes, UK).

10

Vulevic, J et al described in Am. J Clin. Nutr., (2008), 88 : 1438-46 how administering galactooligosaccharides to healthy elderly persons resulted in positive effects on both the faecal microflora composition and the immune response.

15

It has now been found that a galactooligosaccharide having a DP (degree of polymerisation) of 3 or more can directly modulate the inflammatory response of the mammalian intestinal mucosa. In particular, it attenuates the pro-inflammatory chemokine response, in the presence of inflammatory agents. Thus, such a galactooligosaccharide may be useful in treating such intestinal inflammatory conditions as inflammatory bowel disease, colitis, entero necrotizing colitis, pseudomembranous colitis, ulcerative colitis, Crohn's disease, diverticulitis, ischemia, etc.

20

According to the invention there is provided a galactooligosaccharide having a DP of 3 or more for use in the prevention or treatment of inflammation, preferably in the prevention or treatment of intestinal inflammatory disorders. Preferably the galactooligosaccharide has a DP of from 3 to 5.

25

The galactooligosaccharide has the formula for a trisaccharide of Gal-Gal-Glc, for a tetrasaccharide of Gal-Gal-Gal-Glc or for a pentasaccharide of Gal-Gal-Gal-Gal-Glc, where Gal represents a galactose residue and Glc represents a glucose residue. The structures of the galactooligosaccharides are Gal (β 1-6)- Gal (β 1-4)- Glc, Gal (β 1-3)- Gal (β 1-4)-Glc,

30

- 3 -

Gal (β 1-6)- Gal (β 1-6)- Gal (β 1-4)-Glc, and Gal (β 1-6)- Gal (β 1-6)- Gal (β 1-6)- Gal (β 1-4)-Glc. The galactooligosaccharide is preferably selected from the group consisting of the aforementioned galactooligosaccharides.

5 Enterocytes form a single polarized epithelial layer separating the luminal environment from the host. They are active contributors to the host defence. Their innate immune response to any inflammatory stimuli is primarily responsible for rapidly regenerating the barrier function of the epithelium. The epithelium can be induced to express pro-inflammatory cytokines and chemokines that begin the process of recruiting
10 innate immune cells such as neutrophils to the damaged mucosa, if necessary. For example, pro-inflammatory chemokines, such as IL-8, can be stimulated during an immune response by epithelial cells and by macrophages to recruit neutrophils and PMN's (polymorphonuclear leukocytes) to the inflamed mucosa. Macrophage Inflammatory Protein-3 α (MIP-3 α) or CCL20 is another chemokine that elicits the adaptive immune
15 system by activating the lymphocytes and dendritic cells through activation of chemokine receptor CCR6. The IL-8 and MIP-3 α (CCL20) induction indicates the degree of response to an inflammation challenge.

The effect of the galactooligosaccharide on the inflammatory response of different
20 adult colonic cell culture models has been studied. It was found unexpectedly that at physiologic concentrations, it attenuates the pro-inflammatory chemokine response induced by TNF- α inflammatory stimulus in intestinal epithelial cells, ie human enterocytes.

The galactooligosaccharide may be prepared from the commercially available
25 mixture of galactooligosaccharides known as Bimuno by purification using for example size exclusion chromatography using for example a Biogel P2 column maintained at room temperature. The sample may be prepared by dissolving the powder in water 10% w/v and eluting at a rate of 2 ml/min with deionised water.

30 Alternatively, the active fraction of the Bimuno mixture may be prepared by enzymatic transgalactosylation using the appropriate enzyme.

- 4 -

The galactooligosaccharide may be presented as a powder, a syrup or in the form of a soft pastille. It may be administered to a patient suffering from an inflammatory disorder, for example an intestinal inflammatory disorder, daily in an effective dose of the active galactooligosaccharide of from 1 to 10g, preferably from 2 to 5g, most preferably 2.75g.

5 This can be taken in one single dose or in two separate doses several hours apart. The galactooligosaccharide powder may be added to a hot drink or sprinkled on food. The syrup can be consumed by itself or alternatively mixed into a beverage or spread on food. The soft pastille is chewed in the mouth.

10 In order to prevent inflammation the galactooligosaccharide may be administered to an individual in an effective daily dose of 1 to 10g, preferably 2 to 5g, most preferably 2.75g.

According to another aspect of the invention there is provided a method of treating
15 or preventing inflammation, such as intestinal inflammation, comprising administering an effective amount of a galactooligosaccharide.

The present invention will be further described by way of reference to the following examples and figures.

20 Figure 1 shows the effect of B-GOS on the TNF- α induced IL-8 secretion in T84 cells;

Figures 2(A) and (B) show the effect of B-GOS on TNF- α induced IL-8 and MIP-3 α secretion in NCM-460 cells;

Figures 3(A) and (B) show the effect of B-GOS on the expression of IL-8 and MIP-3 α mRNA in TNF- α treated NCM-460 cells;
25

Figures 4(A), (B) and (C) show the effect of B-GOS on the translocation of NF- κ B p65 protein into the nuclei of TNF- α treated NCM-460 cells;

Figures 5 and 6 show the effect of B-GOS on TNF- α induced IL-8 secretion in NCM-460 cells;

30 Figures 7(A) and (B) show the effect of B-GOS on IL-6 and MIP-2 secretion in DSS treated mice;

Figures 8(A) and (B) show the effect of different fractions of

- 5 -

galactooligosaccharides on the production of IL-8 and MIP-3 α respectively; and

Figures 9(A) and (B) show the effect on the production of TNF- α induced IL 8 and MIP-3 α respectively, when NCM460 cells are treated with Bimuno and the DP3 and DP>3 fractions thereof.

5

EXAMPLE 1

Effect of galactooligosaccharides on cytokine secretion

Intestinal epithelial cells were grown to confluence in 24-well plates from an initial concentration of 5×10^5 cells/mL. When the cells reached 70% confluence, they were treated in quadruplicate as follows: (i) negative control, (ii) TNF- α (10 ng/mL) positive control, (iii) B-GOS (5 g/L) and (iv) TNF- α (10 ng/mL) with B-GOS (5 g/L). A concentration of 5 g/L of oligosaccharides was used since this is the physiological concentration of oligosaccharides found in human milk. After 16 hours, supernatants were collected and stored at -20°C for IL-8 and MIP-3 α secretion to be determined later by ELISA. In following experiments, TNF- α was replaced by IL1 β or flagellin.

Quantitation of IL-8. The IL-8 concentration was measured by ELISA as described previously (Claud EC, Savidge T, Walker WA 2003 *Modulation of human intestinal epithelial cell IL-8 secretion by human milk factors. Pediatr Res 53:419-425*). Briefly, each well of a 96-well high bond plate (Nunc Immulon, Fisher Scientific, Middletown, VA, USA) was coated overnight with 100 μ L of 3 μ g/mL mouse anti-human IL-8 monoclonal antibody, washed three times with 200 μ L of 1% BSA in PBS and incubated with 100 μ L of samples at 37°C for one hour. The wells were then washed three times and incubated with 100 μ L of 0.1 μ g/mL biotin-labelled mouse antihuman IL-8 antibody for one hour. After another wash, each well was incubated with 100 μ L horseradish peroxidase, washed again before incubating with 100 μ L O-phenylenediamine dihydrochloride and hydrogen peroxide. The reaction was stopped with 100 μ L 2N H₂SO₄ and the absorbance was read at 490 nm. The concentration of IL-8 in the samples was calculated from the IL-8 standard curve.

30

- 6 -

Quantitation of MIP-3 α . The amount of MIP-3 α secretion was measured by ELISA similar to IL-8, except that the plate was coated overnight with 100 μ L 2.0 μ g/mL mouse anti-human MIP-3 α monoclonal antibody. The detection antibody, biotin-labelled mouse antihuman MIP-3 α antibody, was used as detection antibody at a concentration of 50 ng/mL with a volume of 100 μ L. The concentration of MIP-3 α in the samples was calculated from the MIP-3 α standard curve.

Cell viability assay. B-GOS cytotoxicity was investigated using the trypan blue exclusion test. NCM-460 cells were grown on coverslips from an initial concentration of 2x10⁵ cells/mL. The cells were treated in triplicate with: B-GOS (5 g/L) or control medium. After 16 hours, NCM-460 cells were assayed for cell viability by trypan blue exclusion assay (*Raimondi F, Crivaro V, Capasso L, Maiuri L, Santoro P, Tucci M, Barone MV, Pappacoda S, Paludetto R 2006 Unconjugated bilirubin modulates the intestinal epithelial barrier function in a human-derived in vitro model. Pediatr Res 60:30-33*). There was no significant effect of B-GOS on the viability of the cells at this concentration.

Effect of B-GOS on induction of cytokine transcription. NCM-460 cells were grown to confluence in 6-well plates from an initial concentration of 5x10⁵ cells/mL. When the cells reached 70% confluence, they were treated as follows in quadruplicate: (i) negative control, (ii) TNF- α or IL1 β or flagellin (10 ng/mL) positive control, and (iii) TNF- α or IL1 β or flagellin (10 ng/mL) with B-GOS (5 g/L). After 18 hours, total cellular RNA was isolated by Trizol-chloroform extraction. Using the SuperScript III Platinum SYBR Green One-Step qRT-PCR kit, the mRNA expression of IL-8, MIP-3 α and MCP-1 was measured on a MJ Opticon 2 and standardized to mRNA expression of GAPDH.

Effect of B-GOS on NF- κ B translocation. NCM-460 cells were grown to 70% confluency on cover slips and treated in duplicate for 10 or 30 minutes as follows: (i) negative control, (ii) TNF- α (10 ng/mL) positive control, and (iii) TNF- α (10 ng/mL) with B-GOS (5 g/L). The medium was removed and the cells were fixed in 4% paraformaldehyde. After permeabilization with methanol and blocking with 10% goat

- 7 -

serum in 0.25% BSA in TBS, the cells were probed with rabbit anti-human NF- κ B p65 polyclonal antibody. After washing, the cells were incubated with CyTM 3-conjugated goat anti-rabbit antibody. The cover slips were then washed and mounted on a glass slide to be visualized under the microscope (Nikon Eclipse TE2000-S).

5

Materials

TNF- α cytokine, IL1 β , flagellin, streptavidin-HRP and human CCL20-MIP-3 α ELISA development kits (Quantikine) were obtained from R&D Systems (Minneapolis, MN, USA). Antihuman IL-8 and mouse anti-human IL-8 antibodies were obtained from
10 Pierce Endogen (Woburn, MA, USA). O-phenylenediamine tablets were obtained from Pierce (Rockford, IL, USA). Trizol, SuperScript III Platinum SYBR Green One-Step qRT-PCR kits and other reagents necessary for qRT-PCR were obtained from Invitrogen (Carlsbad, CA, USA). DMEM/F12 medium, CMRL medium, penicillin, streptomycin and Hepes buffer were obtained from Gibco-Invitrogen (Carlsbad, CA, USA). Fetal bovine
15 serum was obtained from Atlanta Biologicals (Lawrenceville, GA, USA). M3D was obtained from Incell Corp. (San Antonio, TX, USA). Rabbit anti-human NF- κ B (p65) polyclonal antibody was obtained from Calbiochem (Gibbstown, NJ, USA). CyTM 3-conjugated F(ab')₂ fragment goat anti-rabbit IgG was obtained from Jackson ImmunoResearch (West Grove, PA, USA). All other reagents for immunofluorescence
20 were obtained from Vector Lab (Burlingame, CA, USA). All other reagents were of analytical or molecular biological grade from Sigma-Aldrich (St. Louis, MO, USA).

B-Galacto-oligosaccharides B-GOS. Bimuno® was supplied by Clasado Ltd., Milton Keynes, UK.

25

Intestinal Epithelial Cell lines. Two adult human intestinal epithelial culture models were used in these studies: T84 and NCM-460 cells are transformed and untransformed colonic epithelial cells, respectively. Cells were cultured in Falcon cell culture dishes at 37°C with 95% O₂ and 5% CO₂ atmosphere saturated with water vapour.
30 T84 culture medium consisted of DMEM/F12 supplemented with FBS (5%), Hepes buffer,

- 8 -

glutamine, non-essential amino acids, penicillin and streptomycin (12). NCM-460 culture medium consisted of M3D medium supplemented with FBS (10%), penicillin and streptomycin as described previously (13).

5 **Statistical analysis.** Induction of cytokines was standardized to the positive control with error bars representing standard error (SE). Comparisons between groups were performed using a two-tailed Student's *t* test. Gene expression data obtained by qRT-PCR was expressed as the mean with SE. Comparisons between groups were performed using a Student's two-tailed *t* test after logarithmic transformation. A *p* value <0.05 was considered
10 statistically significant and indicated by an asterisk (*), a *p* value <0.01 was indicated by two asterisks (**) and a *p* value <0.001 was indicated by three asterisks (***).

Results

15 **Effect of galactooligosaccharides B-GOS on cytokine secretion in T84 cells (Figure 1).**

TNF- α -induced IL-8 secretion in T84 cells was normalized to 100% to allow for comparison between 4 independent experiments. The untreated T84 cells had a basal IL-8 secretion at 20.5%. Upon TNF- α stimulation, IL-8 secretion was significantly increased by 4.9 fold (*p* < 0.001).

20

To determine the effect of B-GOS, T84 cells were stimulated with or without TNF- α in the presence of galacto-oligosaccharides B-GOS (5 g/L). B-GOS-treated T84 cells secreted IL-8 at 16.4%. This was not significantly different from basal level of untreated T84 cells. Upon stimulation with TNF- α , B-GOS significantly attenuated IL-8 secretion by
25 38.5% (*p* < 0.001).

Effect of galactooligosaccharides B-GOS on cytokine secretion in NCM-460 cells (Figure 2, Figure 5, Figure 6).

TNF- α -induced IL-8 and MIP-3 α secretion in NCM-460 cells was normalized to
30 100% to allow for comparison between 4 independent experiments. The untreated NCM-

- 9 -

460 cells had a basal IL-8 and MIP-3 α secretion at 1.7% and 4.0% respectively. Upon TNF- α stimulation, IL-8 and MIP-3 α secretion was significantly increased by 58.8 fold ($p < 0.001$) (Figure 2A) and 25.0 fold ($p < 0.001$) (Figure 2B) respectively.

5 To determine the effect of B-GOS, NCM-460 cells were stimulated with or without TNF- α in the presence of galacto-oligosaccharides B-GOS (5 g/L). B-GOS-treated NCM-460 cells secreted IL-8 and MIP-3 α at 1.1% and 3.9% respectively; this was not significantly different from basal level of untreated NCM-460 cells. Upon stimulation with TNF- α , B-GOS significantly attenuated IL-8 and MIP-3 α secretion by 43.5% ($p < 0.001$)
10 (Figure 2A) and 52.1% ($p < 0.05$) (Figure 2B) respectively. In the same manner, when NCM-460 cells were prewashed with B-GOS prior to TNF- α stimulation, the secretion of IL8 was significantly reduced by 32% ($p < 0.001$) even in the absence of B-GOS (Figure 6). This suggests that constituents of the B-GOS mixture interact with epithelial receptors such as toll-like receptors (TLR) to prevent inflammatory stimulation of the cell.

15

 Similarly upon stimulation with flagellin, B-GOS significantly attenuated IL-8 secretion by 21.5% ($p < 0.05$) (Figure 5). No effect could be observed upon stimulation with IL1 β .

20

 To determine if B-GOS is cytotoxic, NCM-460 cells were incubated for 16 hours with or without B-GOS. B-GOS did not affect cell viability as determined by a trypan blue exclusion assay as described in the methods.

Effect of galacto-oligosaccharides B-GOS on cytokine expression (Figure 3).

25

 Total RNA of TNF- α treated NCM-460 cells was isolated and assayed for IL-8, MIP-3 α and MCP-1 mRNA expression by qRT-PCR. Upon stimulation with TNF- α , IL-8 and MIP-3 α mRNA expression was significantly increased by 12.2 fold ($p < 0.001$) (Figure 3A) and 99.4 fold ($p < 0.001$) (Figure 3B) respectively. No change in MCP-1 mRNA expression was observed between any of the treatment ($p = 0.19$) (data not shown).

30

 To determine the effect of B-GOS, NCM-460 cells were stimulated with TNF- α in the

presence of B-GOS (5 g/L). Galacto-oligosaccharides B-GOS significantly attenuated TNF- α -induced IL-8 and MIP-3 α mRNA expression by 5.7 fold ($p < 0.05$) (Figure 3A) and 58.9 fold ($p < 0.05$) (Figure 3B) respectively. The MCP-1 mRNA expression was reduced by B-GOS but did not reach significance ($p = 0.06$) (data not shown).

5

Effect of galacto-oligosaccharides B-GOS on NF- κ B translocation (Figure 4)

Adult colonic NCM-460 cells were treated with TNF- α (10 ng/mL) and assayed for nuclear translocation of NF- κ B p65 protein. In the vehicle treated control cells (**Figure 4A**), staining for NF- κ B p65 was predominantly in the cytoplasm and the nucleus was free of p65 protein. NF- κ B p65 is clearly translocated into the nuclei after 30 minutes upon stimulation with TNF- α (Figure 4B).

10

However in the presence of B-GOS, TNF- α -induced NF- κ B translocation was partially inhibited at 30 minutes (Figure 4C).

15

EXAMPLE 2

In vivo study of the effect of B-GOS in Dextran Sulphate Sodium induced colitis mouse model

20

Material methods

Two groups (n=24 each) of adult C57BL/6 mice (Jackson Laboratories, Bar Harbour, ME, USA), conventionally raised (CR) and bacteria-depleted (BD) mice, were used to induce colitis. All animals were housed within a 12-h light/dark cycle and had access to mouse chow and water ad libitum.

25

At 6 weeks of age, conventionally colonised mice were housed under conventional conditions with untreated water (CR group) whilst mice in the BD group were fed an antibiotic cocktail in their drinking water for 2 weeks. Kanamycin (8 mg/ml), Gentamicin (0.7 mg/ml), Colistin (34,000 U/ml), Metronidazole (4.3 mg/ml) and Vancomycin (0.9

30

mg/ml) comprised the antibiotic cocktail. Concentrations of antibiotics in the water were calculated based on the average water consumed by age group.

At 8 weeks of age, intestinal colitis was induced by feeding 3.5% DSS (Dextran Sulphate Sodium) (MP Biomedicals, Aurora, OH, USA) in drinking water for 5 days in all mice of both groups (CR and BD). At 10 weeks of age, half the mice of each group started receiving Bimuno (5 g/L) for 7 days. At the end of week 10, the animals were euthanized and their colons were harvested for analysis.

10 *Cytokine measurements*

Murine IL-6 and MIP-2 cytokines were analysed by ELISA (Quantikine, R&D Systems, MN, USA) on colon tissue homogenates according to manufacturer's instructions. Briefly, the proximal colons for each group were collected and homogenised with PBS homogenising buffer containing 1% Triton X-100 supplemented with a cocktail of protease inhibitors. The homogenised solutions were centrifuged at 12,000 rpm for 10 min, and the supernatants were separated into aliquots and stored at -70°C.

Results

20 The capacity of Bimuno to reduce the injury and inflammation of DSS colitis in both groups of mice (CR and BD) compared to the control mice (no Bimuno administration) was determined.

25 In conventional DSS-treated mice, IL-6 and MIP-2 secretion was significantly induced by 2.2 ($p < 0.0001$) and 8.3 fold ($p < 0.0001$) respectively. Bimuno significantly attenuated IL-6 and MIP-2 secretion by 6.6 ($p < 0.0001$) and 5.5 fold ($p < 0.0001$).

30 In BD DSS-treated mice, IL-6 and IP-2 secretion was significantly induced by 6.2 ($p < 0.0001$) and 27.2 fold ($p = 0.0005$) respectively. Bimuno significantly attenuated IL-6 secretion by 3.6 fold ($p < 0.0001$). MIP-2 secretion was reduced by 1.3 fold but this was

- 12 -

found to be not significant ($p = 0.126$).

In summary, conventional DSS-treated mice developed colitis compared to the untreated group. DSS-treated conventional mice supplemented with Bimuno had significantly reduced markers of inflammation (IL-6 and MIP-2) and alleviated symptoms of colitis. The same effect was observed in bacteria-depleted DSS-treated mice. This implies that the observed reduction in inflammation due to Bimuno is not only mediated through the microflora. Bimuno has a direct immune-modulatory effect on the intestinal epithelium in DSS colitis.

EXAMPLE 3

The effect of fractions of Bimuno galactooligosaccharide mixture on the production of MIP-3 α and IL-8 cytokines in the presence of the inflammatory cytokine TNF- α

Materials and methods

GOS fractions collection from Bimuno mixture

In order to separate and collect the different fractions of galactooligosaccharides (DP2 deprived of lactose, DP3 and DP>3), the size exclusion chromatography with a Biogel P2 column (100cm x 5cm) (Pharmacia, UK) maintained at room temperature was used. All the samples were eluted at a rate of 2 ml/min with deionised water and were monitored by 132RI detector (Gilson). The lactose was removed from fraction DP2 through the β -galactosidase BIOLACTA FNS provided by TENNOJI-KU (Osaka, Japan). The hydrolysis was conducted at 40°C, at pH 6.4, using 100mM sodium phosphate solution as buffer, and 1mM of MgCL₂ as cofactor. The carbohydrate content of each fraction was analysed by ion exclusion and ion exchange chromatography on a RCM-MONOSACCHARIDES Rezex HPLC column equipped with LaChrom RI Detector L-7490 MERCK). The oligosaccharides were eluted in deionised water at 0.5 ml/min at 84.4°C.

Cell culture

The NCM460 cell line, derived from normal human colon mucosal epithelium, was provided by INCELL CORPORATION LLC and it was maintained in M3Base medium (INCELL CORPORATION LLC) supplemented with 10% [v/v] foetal bovine serum at 37°C in 95% air, 5% CO₂ humidified environment.

Measurement of cytokine production by NCM460 cultures

NCM460 cells, in concentration of 5×10^5 cells/ml, were plated on 24-well plates and incubated at 37°C in 95% air and 5% CO₂. After 24 hours of incubation, corresponding to 70% of confluence, the cells were treated in triplicate with TNF- α (10ng/ml) (Recombinant Human TNF- α /TNFSF1A – R&D SYSTEMS), fractions of galactooligosaccharides (0.138g/ml of DP2; 0.049g/ml of DP3; 0.041g/ml of DP>3), and mixture of TNF- α and each fraction. The control consisted of cells grown in the medium. The cells were then incubated at 37°C in 95% air, 5% CO₂ for 16 hours. Following the incubation, the supernatant was collected and frozen in aliquots of 200 μ l, and, before testing, was centrifuged at 400 x g for 5 minutes. The concentration of cytokines (MIP-3 α and IL-8) was measured by ELISA assay using the kit QUANTIKINE, provided by R&D Systems (MN, USA).

Results and discussion

The 3 different fractions, collected using the size exclusion chromatography, had the following amount of galactooligosaccharides:

- a) Fraction DP2 contained 90% of galactodisaccharides and the remaining 10% was constituted by monosaccharides (1%), lactose (6%), trisaccharides (2%) and pentaoligosaccharides (1%);
- b) Fraction DP3 contained 97% galactotrisaccharide and 3% of DP4 oligosaccharides;
- c) Fraction DP>3 contained 96% of galactooligosaccharides with DP4 and DP5, and 4% of galactooligosaccharides with DP3.

- 14 -

The effect of the fractions on the production of IL-8 and MIP-3 α is shown in Figure 8(A) and (B), respectively.

For both experiments, the fraction DP3 and DP>3 decreased the secretion of
5 cytokines:

a) DP3 reduced the IL-8 production by 34% and MIP-3 α production by 25% when compared to the TNF- α alone;

b) for the fraction DP>3, the reduction was 35% and 51% for IL-8 and MIP-3 α , respectively.

10

The results for the fraction DP2 were not clear. The reduction for IL-8 secretion was 49%, but this fraction did not have any effect on the MIP-3 α production.

15 **EXAMPLE 4**

The effect of fractions of Bimuno galactooligosaccharide mixture on the production of IL-8 and MIP-3 α cytokines in the presence of the inflammatory cytokine TNF- α compared with Bimuno

20 **Materials and methods**

GOS fractions were prepared from Bimuno as described in Example 3.

Cell cultures

25 Cell cultures of the NCM460 cell line were obtained from the same source as Example 3 and maintained in the same manner.

Measurement of cytokine production by NCM460 cultures

30 NCM460 cells, in concentration of 5×10^5 cells/ml, were plated on 24-well plates and incubated at 37°C in 95% air and 5% CO₂. After 24 hours of incubation,

- 15 -

corresponding to 70% of confluence, the cells were treated in triplicate with TNF- α (10ng/ml) (Recombinant Human TNF- α /TNFSF1A – R&D Systems), and mixture of TNF- α and Bimuno (0.1g/ml), TNF- α and the DP=3 fraction (0.1g/ml) of Bimuno or TNF- α and the DP>3 fraction (0.1g/ml) of Bimuno. The control consisted of cells grown in the medium. The cells were then incubated at 37°C in 95% air, 5% CO₂ for 16 hours. Following the incubation, the supernatant was collected and frozen in aliquots of 200 μ l, and, before testing, was centrifuged at 400 x g for 5 minutes. The concentration of cytokines (MIP-3 and IL-8) was measured by ELISA assay using the kit QUANTIKINE, provided by R&D Systems.

10

Results

The 2 different fractions collected using the size exclusion chromatography had the following amount of galactooligosaccharides:

15

- a) Fraction DP3 contained
- b) Fraction DP>3 contained

The effect of the galactooligosaccharide fractions and Bimuno on the production of IL-8 and MIP-3 α is shown in Figure 9(A) and (B) respectively. From Figures 9(A) and (B) it can be seen that the fraction DP3 reduced the production of IL-8 by 35% more when compared with Bimuno. The reduction in MIP-3 α production was 37% greater using the DP3 fraction when compared with Bimuno.

With the fraction DP>3 the reduction in the production of IL-8 compared with Bimuno was 40% greater, and the reduction in MIP-3 α production was 55% greater.

Conclusion

When fractions DP3 and DP>3 are present in amounts equal to the total

30

- 16 -

galactooligosaccharide mixture (Bimuno) the protective effect against inflammation is significantly higher.

CLAIMS

1. A galactooligosaccharide having a degree of polymerisation of 3 or more for use in prevention or treatment of an inflammatory disorder.
5
2. The galactooligosaccharide for use according to Claim 1 which is selected from the group consisting of trisaccharides Gal (β 1-6) - Gal (β 1-4) - Glc, Gal (β 1-3) - Gal (β 1-4) - Glc, tetrasaccharide Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-4) - Glc and pentasaccharide Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-4) - Glc.
10
3. The galactooligosaccharide according to Claim 1 or Claim 2 for use in the prevention or treatment of an intestinal inflammatory disorder.
4. The galactooligosaccharide according to any one of Claims 1 to 3 for use in the prevention or treatment of colitis, entero-necrotizing colitis, pseudomembranous colitis,
15 ulcerative colitis, Crohn's disease, diverticulitis, ischemia or inflammatory bowel disease.
5. The galactooligosaccharide according to any one of Claims 1 to 4 presented as a powder, a syrup or in the form of a soft pastille.
20
6. The galactooligosaccharide according to Claim 5 wherein from 1g to 10g of the galactooligosaccharide, preferably 2g to 5g of the galactooligosaccharide, most preferably 2.75g of the galactooligosaccharide, are used daily to treat the inflammatory disorder.
- 25 7. The galactooligosaccharide according to Claim 5 wherein from 1 to 10g of the galactooligosaccharide, preferably 2 to 5g of the galactooligosaccharide, most preferably 2.75g of the galactooligosaccharide are used daily to prevent the inflammatory disorder.
8. Use of a galactooligosaccharide having a degree of polymerisation of 3 or more in
30 prevention or treatment of an inflammatory disorder.

- 18 -

9. Use according to Claim 8 wherein the galactooligosaccharide is selected from the group consisting of trisaccharides Gal (β 1-6) - Gal (β 1-4) - Glc, Gal (β 1-3) - Gal (β 1-4) - Glc, tetrasaccharide Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-4) - Glc and pentasaccharide Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-4) - Glc.

5

10. A method for the treatment and/or prevention of an inflammatory disorder comprising orally administering to a mammal an effective amount of a galactooligosaccharide having a degree of polymerisation of 3 or more.

10 11. The method according to Claim 10 wherein the galactooligosaccharide is selected from the group consisting of trisaccharides Gal (β 1-6) - Gal (β 1-4) - Glc, Gal (β 1-3) - Gal (β 1-4) - Glc, tetrasaccharide Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-4) - Glc and pentasaccharide Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-4) - Glc.

15 12. The method according to Claim 10 or Claim 11 wherein the inflammatory disorder is an intestinal inflammatory disorder.

13. The method according to Claim 10 wherein the inflammatory disorder is colitis, entero-necrotizing colitis, pseudomembranous colitis, ulcerative colitis, Crohn's disease,
20 diverticulitis, ischemia or inflammatory bowel disease.

14. The method according to Claim 10 wherein the mammal is a human.

15. The method according to Claim 10 wherein the galactooligosaccharide is
25 administered as a powder, a syrup or in the form of a soft pastille.

16. The method according to Claim 10 wherein the effective daily dose of the active galactooligosaccharide for treating the inflammatory disorder is from 1g to 10g, preferably 2g to 5g, most preferably 2.75g.

30

- 19 -

17. The method according to Claim 10 wherein the effective daily dose of the active galactooligosaccharide for preventing the inflammatory disorder is from 1g to 10g, preferably 2g to 5g, most preferably 2.75g.

Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5




Figure 6




Figure 7A

4/6




Figure 7B

Figure 8A





Figure 8B






Figure 9A




Figure 9B

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2010/050659

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/7016 A61K31/702 A61P29/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2010/023422 A1 (CLASADO INC [PA]; TZORTZIS GEORGIOS [GB]; VULEVIC JELENA [GB]; ATTANAS) 4 March 2010 (2010-03-04) example 2 page 2, line 27 - page 3, line 2 page 3, line 29 - line 30 page 4, line 10 - line 12 page 4, line 14 - line 16	1-17
X	WO 2005/003329 A1 (CLASADO INC [PA]; WYNNE ANTHONY GRAHAM [GB]; GIBSON GLENN [GB]; SLUPIN) 13 January 2005 (2005-01-13) examples 1,4,7 page 14, line 10 - line 16 ----- -/--	1-17



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 June 2010

Date of mailing of the international search report

23/06/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Albayrak, Timur

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2010/050659

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 2004/052121 A1 (NOVARTIS NUTRITION AG [CH]; GIBSON GLENN R [GB]; BEER MICHAEL [CH]) 24 June 2004 (2004-06-24) page 6, line 4 claim 15</p>	<p>1,3-8, 10,12-17</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2010/050659

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010023422	A1	04-03-2010	NONE
WO 2005003329	A1	13-01-2005	AT 360682 T 15-05-2007
		AU 2004254110 A1 13-01-2005	
		BR PI0408911 A 28-03-2006	
		CA 2520043 A1 13-01-2005	
		DE 602004006133 T2 22-11-2007	
		DK 1644482 T3 13-08-2007	
		EP 1644482 A1 12-04-2006	
		ES 2284028 T3 01-11-2007	
		GB 2412380 A 28-09-2005	
		HK 1077323 A1 28-07-2006	
		JP 4384656 B2 16-12-2009	
		JP 2007527199 T 27-09-2007	
		JP 2009189374 A 27-08-2009	
		KR 20050111624 A 25-11-2005	
		MX PA05010349 A 08-03-2006	
		NZ 542482 A 30-05-2008	
		PT 1644482 E 25-06-2007	
		RU 2313572 C2 27-12-2007	
		US 2007274955 A1 29-11-2007	
WO 2004052121	A1	24-06-2004	AU 2003294835 A1 30-06-2004
			BR 0317272 A 08-11-2005
			CA 2508693 A1 24-06-2004
			CN 1731938 A 08-02-2006
			EP 1571923 A1 14-09-2005
			JP 2006509797 T 23-03-2006
			MX PA05006266 A 19-08-2005
			NZ 540576 A 30-03-2007
			RU 2358474 C2 20-06-2009
			US 2004131659 A1 08-07-2004
			ZA 200504385 A 26-07-2006